Starting August 2024, the Agency will process requests via RIMS, expand consultations for China's med device industry, and launch an NPRA pilot project.
Starting August 2024, the Agency for Medicines and Medical Devices will begin processing certain requests through the RIMS system. From August 5, this includes documentary quality control requests for drugs, and from August 12, it will expand to include various clinical trial-related requests, such as importing drugs for trials and reporting on clinical trials.
Three Important Points:
To further support the development of China's medical device industry, Hebei, Shandong, and Hubei Medical Device Innovation Service Stations have been added as participating units for pre-registration technical consultations. These consultations will begin on August 12, 2024, offering high-quality guidance to local medical device manufacturers. Consultations will be held every Thursday, with specific times and locations provided by each service station.
Three Important Points:
Learn more about China Medical Device Registration & Approval.
The NPRA is expanding its reliance approach to include new/additional indication applications through a 12-month pilot project starting on August 1, 2024. The project involves revised categories and criteria, as detailed in Appendix I. While NPRA aims to test new processes, they are also managing a high volume of variation applications with the same resources, making applicant cooperation crucial.
Three Important Points:
Learn more about MDA Malaysia Medical Device Registration.
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.
.png)
As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.
IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.
(3).png)
On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.
Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.